A Study to Assess the Genomic Biomarkers Associated with Immune-Checkpoint Blockade (ICB) Response in Patients with Metastatic Renal Cell Carcinoma
Latest Information Update: 17 Jan 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
Most Recent Events
- 17 Jan 2020 New trial record